RBR-324wqpv尚未招募未知
Double blind controlled clinical study for biological evaluation of Calcium Phosphate and Synthetic Biopolymers
DentsCare Ltda.0 个研究点开始时间: 2021年6月28日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 20Y 至 60Y（—）
入选标准
- •Healthy patients; older than 20 years and with a maximum age of 60 years; do not present any disease at the moment; not using any medication that may alter or compromise the bone healing response (medication for diabetes, autoimmune dysfunction, prolonged corticosteroid therapy or chemotherapy), they cannot be smokers and if in the case of ex-smokers, they must be at least 6 months without smoking before the study); patient should not report a history of anxiety, mood, eating and / or psychotic disorders that could compromise their participation and collaboration in the study
排除标准
- •Age less than 20 years and more than 60 years; pregnant volunteers; drinkers; active smokers; diabetics; osteoporosis patients; participants using medication that can alter or compromise the bone healing response such as prolonged use of corticosteroids and bisphosphonates.
研究者
相似试验
进行中（未招募）
1 期
Double Blind Controlled Clinical Investigation into the Efficacy and Tolerability of subcutaneously administered Treprostinil Sodium in Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary HypertensioEUCTR2008-006441-10-SKMRN-Medical Research Network GmbH100
进行中（未招募）
不适用
Double Blind Controlled Clinical Investigation into the Efficacy and Tolerability of subcutaneously administered Treprostinil Sodium in Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary HypertensioEUCTR2008-006441-10-DEMRN-Medical Research Network GmbH100
进行中（未招募）
1 期
Double blind placebo controlled clinical investigation into the efficacy and tolerability of inhaled treprostinil in patients with severe pulmonary arterial hypertension.EUCTR2004-003236-59-BEnited Therapeutics Corporation220
进行中（未招募）
1 期
Double blind placebo controlled clinical investigation into the efficacy and tolerability of inhaled treprostinil in patients with severe pulmonary arterial hypertension.YHA Class III and IV patients with severe Pulmonary Arterial Hypertension (PAH)EUCTR2004-003236-59-GBnited Therapeutics Corporation220
进行中（未招募）
不适用
Double blind placebo controlled clinical investigation into the efficacy and tolerability of inhaled treprostinil in patients with severe pulmonary arterial hypertension.EUCTR2004-003236-59-DEnited Therapeutics Corporation220